Please provide your email address to receive an email when new articles are posted on . The study examined efficacy of subcutaneous vs. oral administration of carbidopa/levodopa. Subcutaneous infusion ...

Please provide your email address to receive an email when new articles are posted on . 52-week study included 85 adults with Parkinson’s and at least 3 hours/day of “off” time. At week 12, CSAI led ...

Foscarbidopa and foslevodopa are pro-drugs for carbidopa and levodopa, which are standard-of-care Parkinson's treatments. The new treatment, formerly know as ABBV-951, is the first subcutaneous ...

Patients with type 2 diabetes who were initially treated with multiple daily injections were assessed before and after switching to continuous subcutaneous insulin infusion. OPT2MISE was a multicenter ...

VYALEV™ is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease Adults treated with VYALEV ...

A 24-hour continuous subcutaneous infusion of foslevodopa/foscarbidopa improved Parkinson's disease (PD) motor symptoms during all waking hours for patients with ...

The US Food and Drug Administration (FDA) has approved foscarbidopa and foslevodopa (Vyalev, AbbVie), a solution of carbidopa and levodopa prodrugs for 24-hour continuous subcutaneous infusion, for ...

Continuous subcutaneous insulin infusion (CSII) has become an indispensable modality in the management of type 1 diabetes. This therapy employs an insulin pump to deliver both basal and bolus doses, ...

SAN FRANCISCO, July 30, 2020 /PRNewswire/ -- The global continuous subcutaneous insulin infusion market size is expected to reach USD 7.3 billion by 2027, registering a CAGR of10.3% over the forecast ...

A retrospective claims analysis of managed care enrollees with type 2 diabetes mellitus showed that insulin pump therapy reduced antidiabetic drug and healthcare resource use. This study was a ...